Product Details for ANDA 206377
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL)
12.5MG;20MG
Marketing Status: Discontinued
12.5MG;40MG
Marketing Status: Discontinued
25MG;40MG
Marketing Status: Discontinued
12.5MG;20MG
Marketing Status: Discontinued
Active Ingredient: HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Proprietary Name: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 12.5MG;20MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A206377
Product Number: 001
Approval Date: Feb 24, 2023
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL)
Proprietary Name: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 12.5MG;20MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A206377
Product Number: 001
Approval Date: Feb 24, 2023
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
12.5MG;40MG
Marketing Status: Discontinued
Active Ingredient: HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Proprietary Name: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 12.5MG;40MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A206377
Product Number: 002
Approval Date: Feb 24, 2023
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL)
Proprietary Name: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 12.5MG;40MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A206377
Product Number: 002
Approval Date: Feb 24, 2023
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
25MG;40MG
Marketing Status: Discontinued
Active Ingredient: HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Proprietary Name: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 25MG;40MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A206377
Product Number: 003
Approval Date: Feb 24, 2023
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
Proprietary Name: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 25MG;40MG
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A206377
Product Number: 003
Approval Date: Feb 24, 2023
Applicant Holder Full Name: ZYDUS PHARMACEUTICALS USA INC
Marketing Status: Discontinued
Patent and Exclusivity Information